Dendreon

As some of you may know by now, the FDA is supposed to approve DNDN’s Provenge drug on or before May 1 which this weekend. We sold 1/2 of our position a month or so ago for a beautiful profit and we continue to carry a half position.

I am long and bullish on the outcome. I would not necessarily suggesting anyone get really long without a hedge (unless it is a spec play) but the following link suggests some ways to play it with options which offers some protection depending on your bias. Currently call options are pricing in a $13 point or 32% move on an approval.

Good luck to all DNDN holders. Always be hedged in a situation like this unless it is spec money.

http://bit.ly/9FLpIC

Joe


The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment. I or my affiliates may hold positions or other interests in securities mentioned in the Blog, please see my Disclaimer page for my full disclaimer.

blog comments powered by Disqus

In partnership with CNN Money Part of the CNN Network